Study #2023-0040
A phase 1A/B study to evaluate the safety and tolerability of EBC -129 as a single agent and in combination with pembrolizumab in advanced solid tumours
MD Anderson Study Status
Enrolling
Treatment Agent
EBC-129, Pembrolizumab
Description
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumours
Study phase:
Phase I
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-391-3015
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.